The microbiome: The forgotten organ of the astronauts body - Probiotics beyond terrestrial limits

Future Microbiology

Volumn 7, Issue 9, 2012, Pages 1037-1046

  Saei, Amir Ata ^a   Barzegari, Abolfazl ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

antibiotic resistance; cosmonaut; gut; life support system; metagenome; microbiota; microgravity; space; spacecraft; virulence

Indexed keywords

IMMUNOGLOBULIN A; PROBIOTIC AGENT;

ADAPTIVE IMMUNITY; AEROSPACE MEDICINE; ANTIBODY RESPONSE; BACTERIAL VIRULENCE; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; COSMONAUT; DIETARY INTAKE; DISEASE PREDISPOSITION; ENVIRONMENTAL STRESS; HEALTH STATUS; HUMAN; IMMUNITY; INNATE IMMUNITY; INTESTINE FLORA; LACTOBACILLUS RHAMNOSUS; LIFESTYLE; MICROBIOME; MICROFLORA; MICROGRAVITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPACE FLIGHT;

AEROSPACE MEDICINE; ANIMALS; ASTRONAUTS; BACTERIA; BACTERIAL INFECTIONS; GASTROINTESTINAL TRACT; HUMANS; INFANT; METAGENOME; MICE; PROBIOTICS; RESEARCH; SPACE FLIGHT; WEIGHTLESSNESS;

EID: 84866083680     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.82     Document Type: Review

References (100)

1. Gueguinou N, Huin-Schohn C, Bascove M et al. Could spaceflight-associated immune system weakening preclude the expansion of human presence beyond Earth orbit? J. Leukoc. Biol. 86(5), 1027-1038 (2009).
2. White RJ, Averner M. Humans in space. Nature 409(6823), 1115-1118 (2001).
3. Guarner F, Malagelada Jr. Gut flora in health and disease. Lancet 361(9356), 512-519 (2003).
4. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 449(7164), 804-810 (2007).
5. Bischoff SC. 'Gut health': A new objective in medicine? BMC Med. 9(1), 24 (2011).
6. Langkamp-Henken B, Glezer JA, Kudsk KA. Invited review: Immunologic structure and function of the gastrointestinal tract. Nutr. Clin. Pract. 7(3), 100-108 (1992).
7. Barzegari A, Saei AA. Designing probiotics with respect to the native microbiome. Future Microbiol. 7(5), 571-575 (2012).
8. Reid G, Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect. 4(3), 319-324 (2002).
9. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: A role in the treatment of intestinal infection and inflammation? Gut 50(Suppl. 3), III54-III59 (2002).
10. de Vrese M, Rautenberg P, Laue C, Koopmans M, Herremans T, Schrezenmeir J. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. Eur. J. Nutr. 44(7), 406-413 (2005).
11. Zhu B, Wang X, Li L. Human gut microbiome: The second genome of human body. Protein Cell 1(8), 718-725 (2010).
12. Hecht G. Innate mechanisms of epithelial host defense: Spotlight on intestine. Am. J. Physiol. Cell Physiol. 277(3), C351-C358 (1999).
13. Dumas ME, Maibaum EC, Teague C et al. Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: The INTERMAP Study. Anal. Chem. 78(7), 2199-2208 (2006).
14. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: IMPLICATIONS for stressor-induced immunomodulation. Brain Behav. Immun. 25(3), 397-407 (2011).
15. Wilson JW, Ott CM, Höner zu Bentrup K et al. Space flight alters bacterial gene expression and virulence and reveals a role for global regulator Hfq. Proc. Natl Acad. Sci. USA 104(41), 16299-16304 (2007).
16. Klaus DM, Howard HN. Antibiotic efficacy and microbial virulence during space flight. Trends Biotechnol. 24(3), 131-136 (2006).
17. Xiao Y, Liu Y, Wang G, Hao Z, An Y. Simulated microgravity alters growth and microcystin production in Microcystis aeruginosa (cyanophyta). Toxicon 56(1), 1-7 (2010).
18. Chopra V, Fadl AA, Sha J, Chopra S, Galindo CL, Chopra AK. Alterations in the virulence potential of enteric pathogens and bacterial-host cell interactions under simulated microgravity conditions. J. Toxicol. Environ. Health A 69(14), 1345-1370 (2006).
19. Wilson JW, Ott CM, Quick L et al. Media ion composition controls regulatory and virulence response of Salmonella in spaceflight. PLoS One 3(12), e3923 (2008).
20. Nickerson CA, Ott CM, Mister SJ, Morrow BJ, Burns-Keliher L, Pierson DL. Microgravity as a novel environmental signal affecting Salmonella enterica serovar Typhimurium virulence. Infect. Immun. 68(6), 3147-3152 (2000).
21. Nickerson CA, Ott CM, Wilson JW, Ramamurthy R, Pierson DL. Microbial responses to microgravity and other low-shear environments. Microbiol. Mol. Biol. Rev. 68(2), 345-361 (2004).
22. Wilson JW, Ramamurthy R, Porwollik S et al. Microarray analysis identifies Salmonella genes belonging to the low-shear modeled microgravity regulon. Proc. Natl Acad. Sci. USA 99(21), 13807-13812 (2002).
23. Allen CA, Niesel DW, Torres AG. The effects of low-shear stress on adherent- invasive Escherichia coli. Environ. Microbiol. 10(6), 1512-1525 (2008).
24. Searles SC, Woolley CM, Petersen RA, Hyman LE, Nielsen-Preiss SM. Modeled microgravity increases filamentation, biofilm formation, phenotypic switching, and antimicrobial resistance in Candida albicans. Astrobiology 11(8), 825-836 (2011).
25. Lynch SV, Brodie EL, Matin A. Role and regulation of sigma S in general resistance conferred by low-shear simulated microgravity in Escherichia coli. J. Bacteriol. 186(24), 8207-8212 (2004).
26. Chao Y, Vogel J. The role of Hfq in bacterial pathogens. Curr. Opin. Microbiol. 13(1), 24-33 (2010).
27. Costerton JW, Cheng KJ, Geesey GG et al. Bacterial biofilms in nature and disease. Ann. Rev. Microbiol. 41(1), 435-464 (1987).
28. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 13(1), 34-40 (2005).
29. Lynch SV, Mukundakrishnan K, Benoit MR, Ayyaswamy PS, Matin A. Escherichia coli biofilms formed under low-shear modeled microgravity in a ground-based system. Appl. Environ. Microbiol. 72(12), 7701-7710 (2006).
30. Crabbe A, Schurr MJ, Monsieurs P et al. Transcriptional and proteomic responses of Pseudomonas aeruginosa PAO1 to spaceflight conditions involve Hfq regulation and reveal a role for oxygen. Appl. Environ. Microbiol. 77(4), 1221-1230 (2011).
31. Crabbe A, De Boever P, Van Houdt R, Moors H, Mergeay M, Cornelis P. Use of the rotating wall vessel technology to study the effect of shear stress on growth behaviour of Pseudomonas aeruginosa PA01. Environ. Microbiol. 10(8), 2098-2110 (2008).
32. Crabbbe A, Pycke B, Van Houdt R et al. Response of Pseudomonas aeruginosa PAO1 to low shear modelled microgravity involves AlgU regulation. Environ. Microbiol. 12(6), 1545-1564 (2010).
33. Matin A, Lynch SV, Benoit MR. Increased bacterial resistance and virulence in simulated microgravity and its molecular basis. ASGSB 19(2), 31-42 (2006).
34. Tixador R, Richoilley G, Gasset G et al. Study of minimal inhibitory concentration of antibiotics on bacteria cultivated in vitro in space (Cytos 2 experiment). Aviat. Space Environ. Med. 56(8), 748-751 (1985).
35. Tixador R, Richoilley G, Gasset G et al. Preliminary results of Cytos 2 experiment. Acta Astronaut. 12(2), 131-134 (1985).
36. Lapchine L, Moatti N, Gasset G, Richoilley G, Templier J, Tixador R. Antibiotic activity in space. Drugs Exp. Clin. Res. 12(12), 933-938 (1986).
37. Tixador R, Gasset G, Eche B et al. Behavior of bacteria and antibiotics under space conditions. Aviat. Space Environ. Med. 65(6), 551-556 (1994).
38. Taylor PW, Sommer AP. Towards rational treatment of bacterial infections during extended space travel. Int. J. Antimicrob. Agents. 26(3), 183-187 (2005).
39. Fukuda T, Fukuda K, Takahashi A et al. Analysis of deletion mutations of the rpsL gene in the yeast Saccharomyces cerevisiae detected after long-term flight on the Russian space station Mir. Mutat. Res. 470(2), 125-132 (2000).
40. Schuerger AC. Microbial contamination of advanced life support (ALS) systems poses a moderate threat to the long-term stability of space-based bioregenerative systems. Life Support Biosph. Sci. 5(3), 325 (1998).
41. Taylor GR, Henney MR, Ellis WL. Changes in the fungal autoflora of Apollo astronauts. Appl. Microbiol. 26(5), 804-813 (1973).
42. Taylor GR. Space microbiology. Ann. Rev. Microbiol. 28, 121-137 (1974).
43. Lencner AA, Lencner CP, Mikelsaar ME et al. [The quantitative composition of the intestinal lactoflora before and after space flights of different lengths]. Nahrung 28(6-7), 607-613 (1984).
44. Decelle JG, Taylor GR. Autoflora in the upper respiratory tract of Apollo astronauts. Appl. Environ. Microbiol. 32(5), 659-665 (1976).
45. Brown LR, Fromme WJ, Handler SF, Wheatcroft MG, Johnston DA. Effect of Skylab missions on clinical and microbiologic aspects of oral health. J. Am. Dent. Assoc. 93(2), 357-363 (1976).
46. Nefedov YG, Shilov VM, Konstantinova IV, Zaloguyev SN. Microbiological and immunological aspects of extended manned space flights. Life Sci. Space Res. 9, 11-16 (1971).
47. Hales NW, Yamauchi K, Alicea A, Sundaresan A, Pellis NR, Kulkarni AD. A countermeasure to ameliorate immune dysfunction in in vitro simulated microgravity environment: Role of cellular nucleotide nutrition. In Vitro Cell Dev. Biol. Anim. 38(4), 213-217 (2002).
48. Ilyin VK, Kornyushenkova IN, Lizko NN. Space crew members' microbial flora in spaceflight and prospective approaches for its ecological control. in: Life sciences research in space. Presented at: LIFE Sciences Research in Space, Proceedings of the Sixth European Symposium. Trondheim, Norway, 16-18 June 1996.
49. Lizko NN, Silov VM, Syrych GD. [Events in the development of dysbacteriosis of the intestines in man under extreme conditions.] Nahrung 28(6-7), 599-605 (1984).
50. Lizko NN. Problems of microbial ecology in man space mission. Acta Astronaut. 23, 163-169 (1991).
51. Ilyin VK. Microbiological status of cosmonauts during orbital spaceflights on Salyut and Mir orbital stations. Acta Astronaut. 56(9), 839-850 (2005).
52. Canganella F. Microbiologia degli ambienti estremi. In: MICROBIOLOGIA Agroambientale. Biavati B, Sorlini C (Eds.). Casa Editrice Ambrosiana, Milan, Italy, 51-87 (2008).
53. Somova LA, Pechurkin NS. Management and control of microbial populations development in LSS of missions of different durations. Adv. Space Res. 35(9), 1621-1625 (2005).
54. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat. Rev. Immunol. 4(6), 478-485 (2004).
55. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102(3), 448-455 (1995).
56. Masseret E, Boudeau J, Colombel JF et al. Genetically related Escherichia coli strains associated with Crohn's disease. Gut 48(3), 320-325 (2001).
57. Cong Y, Konrad A, Iqbal N, Elson CO. Probiotics and immune regulation of inflammatory bowel diseases. Curr. Drug Targets Inflamm. Allergy 2(2), 145-154 (2003).
58. Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: Effects on immunity. Am. J. Clin. Nutr. 73(2 Suppl.), 444S-450S (2001).
59. Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 105(6), 1643-1650 (1993).
60. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr. Res. 32(2), 141-144 (1992).
61. Sutas Y, Soppi E, Korhonen H et al. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes. J. Allergy Clin. Immunol. 98(1), 216-224 (1996).
62. Gaboriau-Routhiau V, Moreau MC. Gut flora allows recovery of oral tolerance to ovalbumin in mice after transient breakdown mediated by cholera toxin or Escherichia coli heat-labile enterotoxin. Pediatr. Res. 39(4 Pt 1), 625-629 (1996).
63. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9(5), 313-323 (2009).
64. Zaneveld J, Turnbaugh PJ, Lozupone C et al. Host-bacterial coevolution and the search for new drug targets. Curr. Opin. Chem. Biol. 12(1), 109-114 (2008).
65. Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: What we know and need to know from gnotobiology. Microbiol. Mol. Biol. Rev. 62(4), 1157-1170 (1998).
66. Bouskra D, Brezillon C, Berard M et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 456, 507-510 (2008).
67. Tannock GW. Control of gastrointestinal pathogens by normal flora. In: CURRENT Perspectives in Microbial Ecology. Klug MJ, Reddy CA (Eds.). American Society for Microbiology, Washington DC, USA, 374-382 (1984).
68. Sonnenfeld G, Butel JS, Shearer WT. Effects of the space flight environment on the immune system. Rev. Environ. Health 18(1), 1-17 (2003).
69. Kaur I, Simons ER, Castro VA, Mark OC, Pierson DL. Changes in neutrophil functions in astronauts. Brain Behav. Immun. 18(5), 443-450 (2004).
70. Kaur I, Simons ER, Castro VA, Ott CM, Pierson DL. Changes in monocyte functions of astronauts. Brain Behav. Immun. 19(6), 547-554 (2005).
71. Mehta SK, Kaur I, Grimm EA, Smid C, Feeback DL, Pierson DL. Decreased non-MHC-restricted (CD56+) killer cell cytotoxicity after spaceflight. J. Appl. Physiol. 91(4), 1814-1818 (2001).
72. Konstantinova IV, Rykova MP, Lesnyak AT, Antropova EA. Immune changes during long-duration missions. J. Leukoc. Biol. 54(3), 189-201 (1993).
73. Lesnyak A, Sonnenfeld G, Avery L et al. Effect of SLS-2 spaceflight on immunologic parameters of rats. J. Appl. Physiol. 81(1), 178-182 (1996).
74. Lesnyak AT, Sonnenfeld G, Rykova MP, Meshkov DO, Mastro A, Konstantinova I. Immune changes in test animals during spaceflight. J. Leukoc. Biol. 54(3), 214-226 (1993).
75. Meshkov D, Rykova M. The natural cytotoxicity in cosmonauts on board space stations. Acta Astronaut. 36(8-12), 719-726 (1995).
76. Cogoli A. Gravitational physiology of human immune cells: A review of in vivo, ex vivo and in vitro studies. J. Gravit. Physiol. 3(1), 1-9 (1996).
77. Taylor GR, Janney RP. In vivo testing confirms a blunting of the human cell-mediated immune mechanism during space flight. J. Leukoc. Biol. 51(2), 129-132 (1992).
78. Taylor GR, Konstantinova I, Sonnenfeld G, Jennings R. Chapter 1 changes in the immune system during and after spaceflight. Adv. Space Biol. Med. 1-32 (1997).
79. Stowe RP, Sams CF, Pierson DL. Effects of mission duration on neuroimmune responses in astronauts. Aviat. Space Environ. Med. 74(12), 1281-1284 (2003).
80. Stowe RP, Mehta SK, Ferrando AA, Feeback DL, Pierson DL. Immune responses and latent herpesvirus reactivation in spaceflight. Aviat. Space Environ. Med. 72(10), 884-891 (2001).
81. Pierson DL, Stowe RP, Phillips TM, Lugg DJ, Mehta SK. Epstein-Barr virus shedding by astronauts during space flight. Brain Behav. Immun. 19(3), 235-242 (2005).
82. Ball JR, Evans CH. Safe Passage: Astronaut Care For Exploration Missions. National Academy Press, Washington DC, USA (2001).
83. Madsen K. Probiotics and the immune response. J. Clin. Gastroenterol. 40(3), 232-234 (2006).
84. Majamaa H, Isolauri E. Probiotics: A novel approach in the management of food allergy. J. Allergy Clin. Immunol. 99(2), 179-185 (1997).
85. De Simone C, Salvadori BB, Negri R, Ferrazzi M, Baldinelli L, Vesely R. The adjuvant effect of yogurt on production of gammainterferon by ConA-stimulated human peripheral blood lymphocytes. Nutr. Rep. Int. 33, 419-433 (1986).
86. Halpern GM, Vruwink KG, Van de Water J, Keen CL, Gershwin ME. Influence of long-term yoghurt consumption in young adults. Int. J. Immunother. 7, 205-210 (1991).
87. Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect. Immun. 63(10), 3904-3913 (1995).
88. Moreau MC, Hudault S, Bridonneau C. Systemic antibody response to ovalbumin in gnotobiotic C3H/HeJ mice with Bifidobacterium bifidum or Escherichia coli. Microecol. Ther. 20, 309-312 (1990).
89. Yasui H, Nagaoka N, Mike A, Hayakawa K, Ohwaki M. Detection of bifidobacterium strains that induce large quantities of IgA. Microb. Ecol. Health Dis. 5(3), 155-162, (1992).
90. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 20(3), 333-338 (1995).
91. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 13(3), 310-312 (1995).
92. Galdeano CM, Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin. Vaccine Immunol. 13(2), 219-226 (2006).
93. Perdigon G, Maldonado GC, Valdez JC, Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur. J. Clin. Nutr. 56 (Suppl. 4), S21-S26 (2002).
94. Kato I, Yokokura T, Mutai M. Macrophage activation by Lactobacillus casei in mice. Microbiol. Immunol. 27(7), 611-618 (1983).
95. Matsuzaki T, Chin J. Modulating immune responses with probiotic bacteria. Immunol. Cell Biol. 78(1), 67-73 (2000).
96. Lomax AR, Calder PC. Probiotics, immune function, infection and inflammation: A review of the evidence from studies conducted in humans. Curr. Pharm. Des. 15(13), 1428-1518 (2009).
97. Lopez-Varela S, Gonzalez-Gross M, Marcos A. Functional foods and the immune system: A review. Eur. J. Clin. Nutr. 56(Suppl. 3), S29-S33 (2002).
98. Ghosh S, van HD, Playford RJ. Probiotics in inflammatory bowel disease: Is it all gut flora modulation? Gut 53(5), 620-622 (2004).
99. Buckley ND, Champagne CP, Masotti AI, Wagar LE, Tompkins TA, Green-Johnson JM. Harnessing functional food strategies for the health challenges of space travel - fermented soy for astronaut nutrition. Acta Astronauti. 68(7-8), 731-738 (2011).
100. Xu J, Mahowald MA, Ley RE et al. Evolution of symbiotic bacteria in the distal human intestine. PLoS Biol. 5(7), e156 (2007).